{"entity":{"id":"nct06038578","kind":"trial","name":"A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer","aka":[],"tldr":"A phase 2 trial of TRK-950 and Ramucirumab in gastric & gastro-oesophageal junction cancer, run by Toray Industries, Inc, now recruiting.","summary":"A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer is a phase 2 interventional study registered as NCT06038578 by Toray Industries, Inc, with 146 participants planned, started 2023-10-04 and due to reach its primary completion in 2026-06-30. Interventions recorded: TRK-950, Ramucirumab and Paclitaxel.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06038578","url":"https://clinicaltrials.gov/study/NCT06038578"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["gastric"],"sections":[],"technologies":[],"targets":[],"drugs":["trk-950","ramucirumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06038578","phase":"2","setting":"A Randomized, Multicenter, Open-Label, Phase 2 Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer","sponsor":"Toray Industries, Inc","enrolled":146,"outcomes":[]},"route":"/trials/nct06038578/","neighbours":{"cancer":[{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"}],"drug":[{"id":"ramucirumab","kind":"drug","name":"Ramucirumab","route":"/drugs/ramucirumab/"},{"id":"trk-950","kind":"drug","name":"TRK-950","route":"/drugs/trk-950/"}]}}